Save time and jump to the most important pieces.
Date | Price Target | Rating | Analyst |
---|---|---|---|
11/15/2024 | $14.00 | Buy | Goldman |
9/17/2024 | $8.00 → $10.00 | Hold | Jefferies |
2/29/2024 | $22.00 | Overweight | Cantor Fitzgerald |
2/26/2024 | $17.00 | Market Perform | Leerink Partners |
1/17/2024 | $33.00 → $22.00 | Buy → Neutral | DA Davidson |
1/3/2024 | $26.00 | Overweight | Barclays |
4/12/2023 | $25.00 | Equal-Weight | Stephens |
2/23/2023 | $34.00 | Market Perform → Outperform | SVB Securities |
4 - Teladoc Health, Inc. (0001477449) (Issuer)
4 - Teladoc Health, Inc. (0001477449) (Issuer)
4 - Teladoc Health, Inc. (0001477449) (Issuer)
PURCHASE, NY, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Teladoc Health, Inc. (NYSE: TDOC), the global leader in whole-person virtual care, today reported financial results for the full year ended December 31, 2024 ("Full Year 2024") and three months ended December 31, 2024 ("Fourth Quarter 2024"). Unless otherwise noted, percentage and other changes are relative to the full year ended December 31, 2023 ("Full Year 2023") and three months ended December 31, 2023 ("Fourth Quarter 2023"). Full Year and Fourth Quarter 2024 Highlights Full Year 2024 revenue of $2,569.6 million, down 1% year-over-year, and Fourth Quarter 2024 revenue of $640.5 million, down 3% year-over-yearFull Year 2024 net loss of
PURCHASE, NY, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Teladoc Health Inc. (NYSE:TDOC), the global leader in virtual care, announced that it will release fourth quarter 2024 results on Wednesday, February 26, 2025, after the market closes. In conjunction, the company will host a conference call to review results at 4:30 p.m. ET on the same day. Conference Call DetailsThe conference call can be accessed by dialing 1-833-470-1428 for U.S. participants and using the access code # 259200. For international participants, please visit the following link for global dial-in numbers: https://www.netroadshow.com/events/global-numbers?confId=72270. A live audio webcast will also be available online at http
PURCHASE, NY, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Teladoc Health, Inc. (NYSE: TDOC), the global leader in whole-person virtual care, today reported financial results for the three months ended September 30, 2024 ("Third Quarter 2024"). Unless otherwise noted, percentage and other changes are relative to the three months ended September 30, 2023 ("Third Quarter 2023"). Third Quarter 2024 Highlights Third Quarter 2024 revenue of $640.5 million, down 3% year-over-yearThird Quarter 2024 net loss of $33.3 million, or $0.19 per shareThird Quarter 2024 adjusted EBITDA of $83.3 million, down 6% year-over-yearIntegrated Care segment revenue of $383.7 million, up 2% year-over-year, and adjusted EBIT
SC 13G - Teladoc Health, Inc. (0001477449) (Subject)
SC 13G/A - Teladoc Health, Inc. (0001477449) (Subject)
SC 13G/A - Teladoc Health, Inc. (0001477449) (Subject)
4 - Teladoc Health, Inc. (0001477449) (Issuer)
4 - Teladoc Health, Inc. (0001477449) (Issuer)
4 - Teladoc Health, Inc. (0001477449) (Issuer)
Jason Gorevic to depart the company, effective immediatelyCFO Mala Murthy appointed acting chief executiveTeladoc Health reaffirms guidance PURCHASE, NY, April 05, 2024 (GLOBE NEWSWIRE) -- Teladoc Health, Inc. (NYSE:TDOC), the global leader in whole-person virtual care, today announced that Jason Gorevic is departing the company, effective immediately. The Board of Directors has appointed Mala Murthy acting Chief Executive Officer while it searches for Mr. Gorevic's permanent successor. Ms. Murthy is a seasoned industry leader who has served as the Company's Chief Financial Officer since 2019, and she will continue serving in this role during this transition period. The Board has ret
PURCHASE, NY, Sept. 20, 2023 (GLOBE NEWSWIRE) -- Teladoc Health, Inc. (NYSE:TDOC), the global leader in whole-person virtual care, today appointed Eric Evans to the company's board of directors. Mr. Evans, currently chief executive officer and director of Brentwood, TN-based Surgery Partners, Inc. (NASDAQ:SGRY), is a recognized healthcare and hospital executive with significant experience leading complex organizations operating at the intersection of care and technology. Mr. Evans joins the board following the retirement of Senator William Frist, M.D. earlier this year, and will serve on the board's compensation committee. David B. Snow, Jr., non-executive Chairman of the company's board,
After spending two decades successfully scaling multiple healthcare technology companies, Perez joins Big Health to accelerate the commercial coverage and reimbursement for digital therapeutics Big Health, a digital therapeutics company dedicated to helping millions back to good mental health, today announced the appointment of Gabriela Perez as Chief Commercial Officer. In her new role, Perez will oversee Big Health's global commercial growth and strategy, including sales, client management, strategic partnerships, and new markets. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220203005297/en/Big Health Chief Commercial Office
144 - Teladoc Health, Inc. (0001477449) (Subject)
S-8 - Teladoc Health, Inc. (0001477449) (Filer)
10-K - Teladoc Health, Inc. (0001477449) (Filer)
Goldman initiated coverage of Teladoc with a rating of Buy and set a new price target of $14.00
Jefferies reiterated coverage of Teladoc with a rating of Hold and set a new price target of $10.00 from $8.00 previously
Cantor Fitzgerald initiated coverage of Teladoc with a rating of Overweight and set a new price target of $22.00
PURCHASE, NY, March 05, 2025 (GLOBE NEWSWIRE) -- Teladoc Health, Inc. (NYSE:TDOC), the global leader in virtual care, today announced that it issued inducement awards to 21 new employees. Effective February 28, 2025 and March 1, 2025, in connection with the acquisition of Catapult Health on February 28, 2025, 19 employees of Catapult Health were granted awards of restricted stock units covering an aggregate of 365,282 shares of Teladoc Health's common stock, par value $0.001 per share ("Common Stock"), and awards of performance stock units covering a target of 324,270 shares of Common Stock. The restricted stock units vest, based on continued service to Teladoc Health, over two or three y
PURCHASE, NY, March 04, 2025 (GLOBE NEWSWIRE) -- Teladoc Health (NYSE:TDOC), the global leader in virtual care, today announced new capabilities to its purpose-built, proprietary care delivery platform, called Prism, that will strengthen its ability to coordinate care with digital health partners and community care providers. New benefits to clinicians and patients include advanced referrals to Teladoc Health's digital and in-person care partners, while also increasing the value of each virtual care visit, using data insights to support clinicians in closing care gaps and improving population health for sponsoring employers and health plans. The announcement is part of Teladoc Health's
PURCHASE, NY, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Teladoc Health, Inc. (NYSE: TDOC), the global leader in whole-person virtual care, today reported financial results for the full year ended December 31, 2024 ("Full Year 2024") and three months ended December 31, 2024 ("Fourth Quarter 2024"). Unless otherwise noted, percentage and other changes are relative to the full year ended December 31, 2023 ("Full Year 2023") and three months ended December 31, 2023 ("Fourth Quarter 2023"). Full Year and Fourth Quarter 2024 Highlights Full Year 2024 revenue of $2,569.6 million, down 1% year-over-year, and Fourth Quarter 2024 revenue of $640.5 million, down 3% year-over-yearFull Year 2024 net loss of